化疗联合CIK细胞回输治疗老年晚期非小细胞肺癌成本-效果分析  

Cost - effectiveness analysis of chemotherapy combined with autoiogous CIK cells transfusion in the treat- ment of aging advanced non - small - cell lung cancer

作　　者：刘芳[1] 于雁[1] 张华[1] 

机构地区：[1]哈尔滨医科大学附属第三医院内科六病区,哈尔滨150081

出　　处：《实用肿瘤学杂志》2011年第4期336-339,共4页Practical Oncology Journal

摘　　要：目的 探讨化疗联合CIK细胞回输治疗老年晚期非小细胞肺癌疗效和经济学价值,以期为老年晚期非小细胞肺癌的治疗提供参考.方法 晚期非小细胞肺癌患者56例,随机分为两组,在采取常规对症治疗的基础上,治疗组采用单药培美曲塞二钠化疗,二周期后序贯CIK细胞回输生物治疗一周期;对照组采用单药培美曲塞二钠方案化疗二周期.治疗结束后,计算两组平均成本及成本效果值.结果 治疗组完全缓解率为7.14%,有效率为69.7%;对照组完全缓解率为0%,有效率为32.1%.治疗组的治疗效果明显好于对照组,差异有显著性（P=0.008）;两组的治疗成本分别为治疗组37800元,对照组21038元.治疗组的治疗成本明显高于对照组（P＜0.05）,但治疗组的成本效果比C/E值低于对照组,差异有显著性（P＜0.05）.结论 采用CIK细胞回输生物治疗联合单药培美曲塞二钠化疗治疗晚期非小细胞肺癌疗效好,且经济学效果较单药化疗好,值得临床推广.Objective To study the clinical efficacy and economic effectiveness of biochemotherapy in the treatment of aging advanced non - small - cell lung cancer. Methods A total of 56 advanced non small cell lung carcinoma patients were random divided into two groups according to the different chemotherapy regimens ap- plied by using cost - effectiveness analysis in pharmacoeeonomics. Treatment group： Twenty - eight cases with non small cell lung carcinoma were enrolled and underwent chemotherapy with pemetrexed disodium, two cycle therapy followed by transfusion of CIK treatment, one cycle therapy. Control group：Twenty - eight cases with non small cell lung cancer＇ were enrolled and only underwent chemotherapy, two cycle therapy. Results In treatment group, of the 28 cases,2 were CR,18 were PR,effeetive power is 67.9% ;In control group,of the 28 cases,0 were CR, 9 were PR, effective power is 32.1%. two groups contrast is obviously significant. Average cost is 37 800 yuan in treatment group and 21 038 yuan in control group, but cost - effectiveness in treastment group is lower than that in control group, two group contrast is obviously significant. Conclusions Patients with biochemotherapy can benefit from the combination of chemotherapy and autologous CIK transfusion. The treatment can enhance the efficacy of aging advanced non- small- cell lung cancer,and is a acceptable treatment modality in economic effectiveness.

关 键 词：生物化疗 CIK细胞 非小细胞肺癌 成本-效果 

分 类 号：R734.2[医药卫生—肿瘤]